nuvia that they would most like to see improved in future DPP-IV inhibitors is its glucose-lowering efficacy, a lower cost than Januvia would be a more persuasive factor in their decision to prescribe a novel DPP-IV inhibitor," said Decision Resources Analyst Christine Helliwell, Ph.D. "Additionally, MCOs say the cost of a novel DPP-IV inhibitor relative to the cost of Januvia will strongly influence tier placement. As a result, cost could provide an effective differentiating feature for novel DPP-IV inhibitors."
A Clinician and Payer Perspective on Changing Dynamics in the Diabetes Market: Is There Room for New GLP-1 Analogues or DPP-IV Inhibitors? is based on a U.S. survey of 77 primary care physicians, 72 endocrinologists and 20 MCO pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Decision Resources, Inc.
ChristopherPage: 1 2 3 Related medicine news :1
. -Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments-2
. Lumenis UltraPulse TotalFX Treatment Featured on ABCNews 20/20 as a Secret Weapon for Treating for Burn Scars3
. Innovative Prostate Cancer Treatment Known as Sonablate(R) HIFU Now Available at Third Site in India4
. Addiction Treatment Will Help Make Health Reform Affordable, New Analysis Shows5
. Mylan Receives FDA Approval for Generic Version of Thyroid Deficiency Treatment Cytomel(R)6
. Cancer Patients Benefit From Speed, Accuracy of RapidArc Radiotherapy Treatments7
. Beijing Cancer Hospital Becomes First Hospital in Mainland China to Introduce Fast and Precise RapidArc Radiotherapy Cancer Treatments8
. New Outpatient Treatment for Heartburn-Related Problem Stops Esophageal Cancer Before It Starts9
. Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer10
. New Treatments for Alzheimers on the Horizon11
. Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pain and Fever